Author

Joris Wilms

Observed name: J. Wilms

Observed institutions: Roswell Park Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Cornell University, Genmab (Denmark), Weill Cornell Medicine, Moores Cancer Center

OpenAlex ID: A5047591504

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

2010 · William G. Wierda, Thomas J. Kipps, et al. · Journal of Clinical Oncology · 583

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

2008 · Anders Osterborg, Thomas J. Kipps, et al. · Blood · 44

A randomized, double‐blind, placebo‐controlled, dose‐escalation first‐in‐man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX 001, in patients with mild to moderate plaque psoriasis

2017 · S.H. Omland, A. Habicht, et al. · Journal of the European Academy of Dermatology and Venereology · 37

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

2009 · Anders Österborg, Birgitte Biilmann Ronn, et al. · Blood · 11

Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab

2009 · William Wierda, Thomas Kipps, et al. · Clinical Lymphoma & Myeloma · 5

Works count: 5

Citation count: 680

H-index: 5

I10-index: 4